[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614009":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":21,"armGroups":28,"interventions":41,"overallOfficials":50,"centralContacts":54,"locations":60,"responsibleParty":79,"collaborators":21,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":21,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":21,"enrollmentInfo":91,"targetDuration":21,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":21,"overallStatus":100,"whyStopped":21,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Exacerbation frequency","Number of acute bronchiectasis exacerbations per patient during follow-up","12 months",[14,17],{"measure":15,"description":16,"timeFrame":12},"Microbiological clearance","Rate of clearance of Pseudomonas aeruginosa and other pathogens from sputum cultures",{"measure":18,"description":19,"timeFrame":20},"Change in FVC","Change in Forced vital capacity","Baseline and 12 months",null,{"allocation":23,"interventionModel":24,"interventionModelDescription":21,"primaryPurpose":25,"observationalModel":21,"timePerspective":21,"maskingInfo":26},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":27,"maskingDescription":21,"whoMasked":21},"NONE",[29,35],{"label":30,"type":31,"description":32,"interventionNames":33},"Intermittent Moxifloxacin + Standard Care","EXPERIMENTAL","Participants will receive moxifloxacin 400 mg orally once daily for 7 days every 8 weeks (total 6 cycles over 12 months) in addition to guideline-based standard care",[34],"Drug: Intermittent Moxifloxacin + Standard Care",{"label":36,"type":37,"description":38,"interventionNames":39},"Standard Care (Control)","ACTIVE_COMPARATOR","Participants will receive guideline-based standard care without long-term suppressive antibiotics.",[40],"Other: Standard Care (in control arm)",[42,46],{"type":43,"name":30,"description":44,"armGroupLabels":45,"otherNames":21},"DRUG","Moxifloxacin 400 mg orally once daily for 7 days every 8 weeks (total 6 cycles over 12 months), in addition to guideline-based standard care",[30],{"type":6,"name":47,"description":48,"armGroupLabels":49,"otherNames":21},"Standard Care (in control arm)","Participants will receive guideline-based management of bronchiectasis without long-term suppressive antibiotics.",[36],[51],{"name":52,"affiliation":5,"role":53},"montaser gamal ahmed, gamal ahmed","PRINCIPAL_INVESTIGATOR",[55],{"name":56,"role":57,"phone":58,"phoneExt":21,"email":59},"montaser gamal ahmed, lecturer","CONTACT","+201008951058","montaser_zahran@yahoo.com",[61],{"facility":62,"status":21,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Assiut University hospital","Asyut","Asyut Governorate","71515","Egypt","EG",{"type":69,"coordinates":70},"Point",[71,72],31.18368,27.18096,{"lat":72,"lon":71},[75],{"name":76,"role":57,"phone":77,"phoneExt":21,"email":78},"Montaser Gamal Elddin, Lecturer","+21008951058","Montaser_zahran@yahoo.com",{"type":53,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Montaser Gamal Ahmed","Lecturer of Chest Diseases and Tuberculosis","100614009","phase-3-long-term-safety-and-efficacy-of-moxifloxacin-in-bronchiectasis-patients-100614009",false,"NCT07274020","Long-Term Safety and Efficacy of Moxifloxacin in Bronchiectasis Patients","Effectiveness and Safety of Long-Term Intermittent Moxifloxacin Eradication Therapy in Non-Cystic Fibrosis Bronchiectasis: A 12-Month Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults ≥18 years of age.\n* Confirmed diagnosis of non-cystic fibrosis bronchiectasis by high-resolution CT (HRCT).\n* History of ≥2 bronchiectasis exacerbations in the previous 12 months.\n\nExclusion Criteria:\n\n* Diagnosis of cystic fibrosis-related bronchiectasis.\n* Known hypersensitivity or contraindication to fluoroquinolones (including moxifloxacin).\n* Severe hepatic impairment or severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* Pregnancy or breastfeeding.\n* History of significant QT prolongation, arrhythmia, or concurrent use of QT-prolonging drugs.\n* Use of long-term suppressive antibiotics for bronchiectasis in the past 3 months.","ALL","18 Years",{"count":92,"type":93},140,"ESTIMATED","INTERVENTIONAL",[96],"PHASE3","Bronchiectasis is a chronic respiratory disease characterized by recurrent infections, inflammation, and progressive lung damage. Frequent exacerbations are associated with increased morbidity, accelerated lung function decline, and reduced quality of life. Preventing exacerbations is a key therapeutic goal. Moxifloxacin, a fluoroquinolone antibiotic with broad-spectrum activity, may play a role in intermittent eradication therapy to reduce bacterial load, achieve microbiological clearance, and minimize exacerbation frequency.\n\nThis randomized controlled trial will evaluate the effectiveness and safety of long-term intermittent moxifloxacin therapy compared with standard care in patients with non-cystic fibrosis bronchiectasis.",[99],"Bronchiectasis, Non-Cystic Fibrosis","NOT_YET_RECRUITING","2025-12-09",{"date":103,"type":104},"2025-12-10","ACTUAL",{"date":106,"type":93},"2025-12-01",{"date":108,"type":93},"2027-01-01",{"name":5,"class":6},1]